Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

592 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nicotine in E-cigarette smoke: cancer culprit?
Saji S, Patil SS, Alleyn M, Lockey R, Kolliputi N. Saji S, et al. J Cell Commun Signal. 2020 Mar;14(1):127-128. doi: 10.1007/s12079-019-00519-5. Epub 2019 Dec 18. J Cell Commun Signal. 2020. PMID: 31853716 Free PMC article.
Altered expression of p63 isoforms and expansion of p63- and club cell secretory protein-positive epithelial cells in the lung as novel features of aging.
Fukumoto J, Sidramagowda Patil S, Krishnamurthy S, Saji S, John I, Narala VR, Hernández-Cuervo H, Alleyn M, Breitzig MT, Galam L, Soundararajan R, Chaudhari UK, Hansen BC, Lockey RF, Kolliputi N. Fukumoto J, et al. Among authors: saji s. Am J Physiol Cell Physiol. 2019 Apr 1;316(4):C492-C508. doi: 10.1152/ajpcell.00330.2018. Epub 2019 Jan 16. Am J Physiol Cell Physiol. 2019. PMID: 30649915 Free PMC article.
Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial.
Yamashita T, Saji S, Takano T, Naito Y, Tsuneizumi M, Yoshimura A, Takahashi M, Tsurutani J, Iwatani T, Kitada M, Tada H, Mori N, Higuchi T, Iwasa T, Araki K, Koizumi K, Hasegawa H, Uchida Y, Morita S, Masuda N. Yamashita T, et al. Among authors: saji s. J Clin Oncol. 2025 Jan 9:JCO2401888. doi: 10.1200/JCO-24-01888. Online ahead of print. J Clin Oncol. 2025. PMID: 39787453
Impact of extended endocrine therapy for patients with risk factors for late recurrence in estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after 5 years of endocrine therapy.
Ito M, Amari M, Sato A, Hikichi M, Tsurumi N, Otofuji H, Saji S. Ito M, et al. Among authors: saji s. Breast Cancer Res Treat. 2024 Oct 17. doi: 10.1007/s10549-024-07509-1. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39417907
592 results